OCTS USA 2022

OCTS USA 2022 (June 29-30)

Delivering Safe and Effective Adoptive Cell Therapy Products to Clinical Promise, Commercial Scale Manufacturing and Patients

Download 2022 Agenda

Why Attend

The Onco Cell Therapy Summit (OCTS) is the only industry-led meeting covering the full range of autologous and allogeneic cell product advancements. A four-tracked agenda, featuring pioneering biopharma, academia, and solution-providers, will address all innovative MoA, manufacturing challenges, and clinical progress of CAR T, TCR T, TILs, Macrophages, and NK cells in treating haematological and solid tumors. Expect to hear from CXOs, VPs, R&D and Process Developers on the opportunities generated from recent clinical and technological data, and how they are tackling the most pressing industry challenges to get effective treatments to patients.

To facilitate connections between relevant peers and spark solution-led discussions, the summit is broken down into four streamlined tracks – Pre-clinical & Translational Research, Clinical, Manufacturing and Logistics & Market Access. You will be able to step into interactive discussions and engaging presentations on the key product development questions:

1. How to expand the durability of response by targeting antigen heterogeneity, optimized affinity, specificity and reduce cell exhaustion in the TME?
2. How can genome editing technologies lead to successful clinical applications?
3. What clinical progress is being made in 'off-the-shelf' allogeneic cell therapies?
4. How to make the transition from proven research-scale to production-scale through a robust manufacturing platform?
5. Where to direct resources to build resilience and create a ‘vein-to-vein’ and IPSC-derived, patient-centric cell therapy supply chain?

OCTS will enable your teams to identify the rationale and progress in developing cell engineering platforms to generate a robust pipeline of potent, safe therapies. There will be a 360-view of the ongoing phase 1 / 2 trials, building out cGMP manufacturing capabilities through automation and in-process analytics, recalibrating supply chains to build resilience in a dynamic research field and ensuring novel therapies address unmet clinical need.

WHO WILL BE THERE

Network with industry experts from:

  • Senior-level leaders from biotech and representatives from big pharma
  • Academic experts in cell therapy
  • Process standardisation - technology/services
  • Logistics companies - cell storage/transport
  • Service providers – CROs, CDMOs, consultants, logistics companies and more

Last year's attendees included:

Confirmed 2022 Speakers

 

Francesco Marincola

Global Head of R&D
Kite Pharma

Francesco Marincola

Global Head of R&D
Kite Pharma

Francesco Marincola

Global Head of R&D
Kite Pharma
 

Peter Bross

Chief, Oncology Branch, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research
FDA

Peter Bross

Chief, Oncology Branch, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research
FDA

Peter Bross

Chief, Oncology Branch, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research
FDA
 

Crystal L Mackall MD

Director
Stanford Center for Cancer Cell Therapy

Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine 

Director, Stanford Center for Cancer Cell Therapy 

Director, Parker Institute for Cancer Immunotherapy at Stanford 

Co-Executive Director, Stanford Laboratory for Cell and Gene Medicine 

Associate Director, Stanford Cancer Institute 

Crystal L Mackall MD

Director
Stanford Center for Cancer Cell Therapy

Crystal L Mackall MD

Director
Stanford Center for Cancer Cell Therapy

Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine 

Director, Stanford Center for Cancer Cell Therapy 

Director, Parker Institute for Cancer Immunotherapy at Stanford 

Co-Executive Director, Stanford Laboratory for Cell and Gene Medicine 

Associate Director, Stanford Cancer Institute 

 

Rafael Amado

Executive Vice President, Head of R&D and CMO
Allogene Therapeutics

Rafael Amado

Executive Vice President, Head of R&D and CMO
Allogene Therapeutics

Rafael Amado

Executive Vice President, Head of R&D and CMO
Allogene Therapeutics
 

Vered Caplan

CEO
Orgenesis

Vered Caplan

CEO
Orgenesis

Vered Caplan

CEO
Orgenesis
 

Birgit Schultes

Senior VP, Head of Cell Therapies
Intellia Therapeutics

Birgit Schultes

Senior VP, Head of Cell Therapies
Intellia Therapeutics

Birgit Schultes

Senior VP, Head of Cell Therapies
Intellia Therapeutics
 

Snehal Patel

SVP, Head of Manufacturing
Sana Biotechnology

Snehal Patel

SVP, Head of Manufacturing
Sana Biotechnology

Snehal Patel

SVP, Head of Manufacturing
Sana Biotechnology
 

Serena De Vita

Clinical Program Leader & Senior Director
Novartis Institutes for BioMedical Research

Serena De Vita

Clinical Program Leader & Senior Director
Novartis Institutes for BioMedical Research

Serena De Vita

Clinical Program Leader & Senior Director
Novartis Institutes for BioMedical Research
 

Debora Barton, MD

Chief Medical Officer
Carisma Therapeutics Inc.

Debora Barton, MD

Chief Medical Officer
Carisma Therapeutics Inc.

Debora Barton, MD

Chief Medical Officer
Carisma Therapeutics Inc.
 

Kate Rochlin

Chief Operating Officer
In8Bio

Kate Rochlin

Chief Operating Officer
In8Bio

Kate Rochlin

Chief Operating Officer
In8Bio
 

Christopher Pastorello

Director, Head of Manufacturing
Century

Christopher Pastorello

Director, Head of Manufacturing
Century

Christopher Pastorello

Director, Head of Manufacturing
Century
 

Lucas Harrington

Co-founder and CSO
Mammoth Biosciences

Lucas Harrington

Co-founder and CSO
Mammoth Biosciences

Lucas Harrington

Co-founder and CSO
Mammoth Biosciences
 

Robbie Majzner

Assistant Professor, Pediatrics
Stanford University School of Medicine

Robbie Majzner

Assistant Professor, Pediatrics
Stanford University School of Medicine

Robbie Majzner

Assistant Professor, Pediatrics
Stanford University School of Medicine
 

Brian Cuffel

VP and Head of Oncology Market Access
Bayer Pharmaceuticals, Oncology SBU

Brian Cuffel

VP and Head of Oncology Market Access
Bayer Pharmaceuticals, Oncology SBU

Brian Cuffel

VP and Head of Oncology Market Access
Bayer Pharmaceuticals, Oncology SBU
 

Kim Noonan

CSO
WindMIL

Kim Noonan

CSO
WindMIL

Kim Noonan

CSO
WindMIL
 

Eric Halioua

CEO
PDC*Line pharma

Eric Halioua

CEO
PDC*Line pharma

Eric Halioua

CEO
PDC*Line pharma
 

Alexander Kamb

CSO
A2 Biotherapeutics

Alexander Kamb

CSO
A2 Biotherapeutics

Alexander Kamb

CSO
A2 Biotherapeutics
 

Cheng Liu

Founder, President and CEO
Eureka

Cheng Liu

Founder, President and CEO
Eureka

Cheng Liu

Founder, President and CEO
Eureka
 

Angela Scott

Co-founder and COO
TC Biopharm

Angela Scott

Co-founder and COO
TC Biopharm

Angela Scott

Co-founder and COO
TC Biopharm
 

Carnley Norman

Vice President of Global Manufacturing Sciences and Technology (MSAT)
Kite Pharma

Carnley Norman

Vice President of Global Manufacturing Sciences and Technology (MSAT)
Kite Pharma

Carnley Norman

Vice President of Global Manufacturing Sciences and Technology (MSAT)
Kite Pharma
 

Anthony Colenburg Sr.

Director of Quality
Adicet Bio

Anthony Colenburg Sr.

Director of Quality
Adicet Bio

Anthony Colenburg Sr.

Director of Quality
Adicet Bio
 

Austin Boesch

Director, Head of Protein Sciences
Tidal Therapeutics

Austin Boesch

Director, Head of Protein Sciences
Tidal Therapeutics

Austin Boesch

Director, Head of Protein Sciences
Tidal Therapeutics
 

Christian Hinrichs

Chief of the Section of Cancer Immunotherapy
Rutgers Cancer Institute of New Jersey

Christian Hinrichs

Chief of the Section of Cancer Immunotherapy
Rutgers Cancer Institute of New Jersey

Christian Hinrichs

Chief of the Section of Cancer Immunotherapy
Rutgers Cancer Institute of New Jersey
 

Stefanie Bailey

Research Fellow
Massachusetts General Hospital and Harvard Medical School

Stefanie Bailey

Research Fellow
Massachusetts General Hospital and Harvard Medical School

Stefanie Bailey

Research Fellow
Massachusetts General Hospital and Harvard Medical School
 

Michael Leek

Co-founder and Executive Chairman
TC Biopharm

Michael Leek

Co-founder and Executive Chairman
TC Biopharm

Michael Leek

Co-founder and Executive Chairman
TC Biopharm
 

Paul Rennert

President & Chief Scientific Officer
Aleta Biotherapeutics

Paul Rennert

President & Chief Scientific Officer
Aleta Biotherapeutics

Paul Rennert

President & Chief Scientific Officer
Aleta Biotherapeutics
 

Guanglin Yu

Senior Expert Science & Technology
Novartis

Guanglin Yu

Senior Expert Science & Technology
Novartis

Guanglin Yu

Senior Expert Science & Technology
Novartis
 

Adham Bear

Instructor of Medicine
Division of Hematology and Oncology, Hospital of the University of Pennsylvania

Adham Bear

Instructor of Medicine
Division of Hematology and Oncology, Hospital of the University of Pennsylvania

Adham Bear

Instructor of Medicine
Division of Hematology and Oncology, Hospital of the University of Pennsylvania
 

Moonsoo Jin

Professor of Biomedical Engineering in Radiology, Radiology; Co-founder
Weill Cornell Medical College; Affyimmune

Moonsoo Jin

Professor of Biomedical Engineering in Radiology, Radiology; Co-founder
Weill Cornell Medical College; Affyimmune

Moonsoo Jin

Professor of Biomedical Engineering in Radiology, Radiology; Co-founder
Weill Cornell Medical College; Affyimmune
 

Mark Yarmarkovich

Senior Scientist
Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia

Mark Yarmarkovich

Senior Scientist
Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia

Mark Yarmarkovich

Senior Scientist
Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia
 

Jorge Mansilla-Soto

Senior Research Scientist
The Michel Sadelain Lab, Sloan Kettering Insititute, Memorial Sloan Kettering Cancer Center

Jorge Mansilla-Soto

Senior Research Scientist
The Michel Sadelain Lab, Sloan Kettering Insititute, Memorial Sloan Kettering Cancer Center

Jorge Mansilla-Soto

Senior Research Scientist
The Michel Sadelain Lab, Sloan Kettering Insititute, Memorial Sloan Kettering Cancer Center
 

Rudy Gonzalez

Executive Director, Stem Cell Therapeutics
Caribou Biosciences

Rudy Gonzalez

Executive Director, Stem Cell Therapeutics
Caribou Biosciences

Rudy Gonzalez

Executive Director, Stem Cell Therapeutics
Caribou Biosciences
 

John Lu

President and CEO
HebeCell

John Lu

President and CEO
HebeCell

John Lu

President and CEO
HebeCell
 

Branden Moriarity

Chief Innovation Officer
Luminary Therapeutics

Branden Moriarity

Chief Innovation Officer
Luminary Therapeutics

Branden Moriarity

Chief Innovation Officer
Luminary Therapeutics
 

Chen Schor

President and CEO
Adicet Bio

Chen Schor

President and CEO
Adicet Bio

Chen Schor

President and CEO
Adicet Bio
 

Jan ter Meulen

CSO
Obsidian Therapeutics

Jan ter Meulen

CSO
Obsidian Therapeutics

Jan ter Meulen

CSO
Obsidian Therapeutics
 

Gavin MacBeath

CSO
Tscan Therapeutics

Gavin MacBeath

CSO
Tscan Therapeutics

Gavin MacBeath

CSO
Tscan Therapeutics
 

Alba Gonzalez

Associate Director R&D
Senti Bio

Alba Gonzalez

Associate Director R&D
Senti Bio

Alba Gonzalez

Associate Director R&D
Senti Bio
 

Will Singleterry

Commercial Director - Immuno-Oncology
LUMICKS

Will Singleterry

Commercial Director - Immuno-Oncology
LUMICKS

Will Singleterry

Commercial Director - Immuno-Oncology
LUMICKS
 

Amanda Conerty

Sr. Director of CMC
Artiva Biotherapeutics

Amanda Conerty

Sr. Director of CMC
Artiva Biotherapeutics

Amanda Conerty

Sr. Director of CMC
Artiva Biotherapeutics
 

David Brochu

CTO
Autolus Therapeutics

David Brochu

CTO
Autolus Therapeutics

David Brochu

CTO
Autolus Therapeutics
 

Jeffrey S Miller

Professor of Medicine, Division of Hematology, Oncology and Transplantation
University of Minnesota Medical School

Jeffrey S Miller

Professor of Medicine, Division of Hematology, Oncology and Transplantation
University of Minnesota Medical School

Jeffrey S Miller

Professor of Medicine, Division of Hematology, Oncology and Transplantation
University of Minnesota Medical School
 

Jennifer Buell

President and CEO
MiNK Therapeutics

Jennifer Buell

President and CEO
MiNK Therapeutics

Jennifer Buell

President and CEO
MiNK Therapeutics
 

Lucas de Breed

Founder
August Care

Lucas de Breed

Founder
August Care

Lucas de Breed

Founder
August Care
 

Matthew Li

Associate Director, Head of Cell Therapy Manufacturing Innovation
Vor Biopharma

Matthew Li

Associate Director, Head of Cell Therapy Manufacturing Innovation
Vor Biopharma

Matthew Li

Associate Director, Head of Cell Therapy Manufacturing Innovation
Vor Biopharma
 

Peggy Sotiropoulu

Chief Scientific Officer
T-Knife Therapeutics

Peggy Sotiropoulu

Chief Scientific Officer
T-Knife Therapeutics

Peggy Sotiropoulu

Chief Scientific Officer
T-Knife Therapeutics
 

Phil Johnson

CEO
Interius BioTherapeutics

Phil Johnson

CEO
Interius BioTherapeutics

Phil Johnson

CEO
Interius BioTherapeutics
 

Stephen Santoro

Senior Director, ICT Cell Development
Arsenal Biosciences

Stephen Santoro

Senior Director, ICT Cell Development
Arsenal Biosciences

Stephen Santoro

Senior Director, ICT Cell Development
Arsenal Biosciences
 

Gail Turner

Senior Principal Scientist, Preclinical Sciences, Immune Oncology and Cell Therapy Thematic Research Center
Bristol Myers Squibb

Gail Turner

Senior Principal Scientist, Preclinical Sciences, Immune Oncology and Cell Therapy Thematic Research Center
Bristol Myers Squibb

Gail Turner

Senior Principal Scientist, Preclinical Sciences, Immune Oncology and Cell Therapy Thematic Research Center
Bristol Myers Squibb
 

Melissa Sebok

Executive Director – Product, Client & Business Development, Direct Patient Care & Emerging Offerings
American Red Cross

Melissa Sebok

Executive Director – Product, Client & Business Development, Direct Patient Care & Emerging Offerings
American Red Cross

Melissa Sebok

Executive Director – Product, Client & Business Development, Direct Patient Care & Emerging Offerings
American Red Cross
 

Reagan Jarvis

CEO
Anocca AB

Reagan Jarvis

CEO
Anocca AB

Reagan Jarvis

CEO
Anocca AB
 

Markus Gruell

Site Quality Head, Qualified Person
Autolus

Markus Gruell

Site Quality Head, Qualified Person
Autolus

Markus Gruell

Site Quality Head, Qualified Person
Autolus
 

Robert Tighe

Vice President, Research
TCR2 Therapeutics

Robert Tighe

Vice President, Research
TCR2 Therapeutics

Robert Tighe

Vice President, Research
TCR2 Therapeutics
 

Christina Bailey

Director, Cell and Gene Therapy, NanoString Technologies
Nanostring

Christina Bailey

Director, Cell and Gene Therapy, NanoString Technologies
Nanostring

Christina Bailey

Director, Cell and Gene Therapy, NanoString Technologies
Nanostring
 

Laura Johnson

Chief Scientific Officer
Verismo Therapeutics

Laura Johnson

Chief Scientific Officer
Verismo Therapeutics

Laura Johnson

Chief Scientific Officer
Verismo Therapeutics
 

Markus Throsby

COO / CSO
Gadeta BV

Markus Throsby

COO / CSO
Gadeta BV

Markus Throsby

COO / CSO
Gadeta BV
 

Steven Doares

SVP & Site Head, US Manufacturing
Cellectis

Steven Doares

SVP & Site Head, US Manufacturing
Cellectis

Steven Doares

SVP & Site Head, US Manufacturing
Cellectis

Get The Agenda

What's New For 2022?

  • Dedicated ‘Preclinical and Translational Science’ track focused on ‘Developing Versatile Cell Therapy Engineering Platforms, with specific talks on targeting antigen heterogeneity (Talks from A2 Biotherapeutics, T-Knife Therapeutics, Enara Bio, Eureka Therapeutics), improving cell therapy durability (Talks from Aleta Biotherapeutics, TCR2 Therapeutics), harnessing innate immune cells (Talks from Senti Bio, Caribou Biosciences).
  • Specific talks and discussion on gene modification strategies for next-generation cell therapy products (Talks from Intellia Therapeutics, Allogene Therapeutics, Mammoth Biosciences, In8bio).
  • What clinical progress is being made in 'off-the-shelf' allogeneic cell therapies (Talks from Rutgers Cancer Institute of New Jersey, MiNK Therapeutics, PDC*Line Pharma).
  • Focused track on developing manufacturing capabilities on a clinical scale and scaling into the commercial setting (Talks from TC Biopharm, Century Therapeutics, Bristol Myers Squibb, Kite Pharma).
  • As more biotechs look beyond clinical development and plan for future market access strategies, OCTS 2022 now has dedicated sessions addressing this subject (Talks from Bayer Pharmaceuticals, Instil Bio, August Care).


Download The 2022 Agenda

Partners

Platinum Partner

Gold Partners

Event Partners

Exhibitors

Media Partners

Non-Profit Partner

PARTNER WITH US

Based on your objectives, we can create bespoke packages designed specifically for you. From presenting your expertize on the main stage to hosting the infamous CAR-T Party. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

Take a look at the Sponsorship Prospectus for more details, or discuss your objectives with Ryan Sanderson, Commercial Partnerships Director; [email protected].

DOWNLOAD THE SPONSORSHIP PROSPECTUS HERE.

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact Laura Hobson, Senior Marketing Manager; [email protected]

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 5% Off
Book a Team of 5+ - Save an Additional 10% Off
Book a Team of 10+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket price will increase in

Saturday, April 23, 2022 to Saturday, May 28, 2022
Tier 1 - Academics
$1299
Early bird pricing until May 27, 2022. Register now to save $200!
Saturday, April 23, 2022 to Saturday, May 28, 2022
Tier 2 - Biotech & Pharma
$2399
Early bird pricing until May 27, 2022. Register now to save $300!
Saturday, April 23, 2022 to Saturday, May 28, 2022
Tier 3 - Service Provider
$3399
Early bird pricing until May 27, 2022. Register now to save $300!
Preparing registration...

Terms & Conditions

In the event that Kisaco Research postpones an event for any reason or changes the event format to ‘virtual event’, any in-person registrations for this event will be automatically transferred to the virtual registration package. The delegate will receive a credit note for the difference in ticket value from the fee paid. You may use this credit for another Kisaco Research event to be mutually agreed with Kisaco Research, which must occur within 12 months from the date of the event which the delegate had originally registered for.

POSTER SUBMISSION

Are you looking to showcase your recent work to the OCTS community?

Our dedicated poster session is the perfect way to get your research noticed. To present a poster, you need to register as a delegate. Please note that there is limited space available, and poster space is assigned on a first-come, first-served basis (subject to checks and successful registration). At the event, your presentation will be displayed in a dedicated poster area. The poster presentation session time of taking place is to be confirmed.

The poster abstract submission deadline is on 3rd June.

Abstracts received after this time may not be accepted, so please submit your abstract as soon as possible! Academics that submit a poster abstract before 3rd June get a 40% discount!

Posters should be sized A0 (841mm x 1189mm) in portrait orientation.

If you have any questions, please contact [email protected]

Click HERE to make a submission.

Resources

Download Resource

OCTS Innovation Awards 2022

The OCTS Innovation Awards, part of the Onco Cell Therapy Summit in Boston (June 29-30), are a fantastic opportunity to recognise leaders and pioneers who have been instrumental to innovation in an incredibly exciting year for the cell therapy industry.

The awards are a people’s choice vote for excellence in cell therapy. We will open up nominations and voting to a universal network of industry leaders.

If you, or someone you know, has spearheaded innovation in cell therapy, or has been pivotal in the implementation of in-house innovation, we want to celebrate your achievements and empower you for future success!

CATEGORIES FOR 2022:

Start-Up of the Year

For start-ups leading the way in innovation, putting great ideas first while positively impacting the future of cell and gene therapy.

Nominate a business

Solution Provider of the Year

For organisations who have demonstrated passion, skill, and expertise in developing a world class solution/service in cell and gene therapy.

Nominate a business

Biotech Innovator of the Year

Celebrating the outstanding contribution of an individual who is driving meaningful change or spearheading innovative projects.

Nominate an individual

Venue

Hynes Convention Center

900 Boylston St, Boston, MA 02115, United States

To view local hotels near to the event venue please click here: https://hotelmap.com/hotels/MLSLZ

Returning Safely Measures

Whether sponsors, speakers or attendees, our customers attend Kisaco Research events to connect, learn and innovate to know more and do business. It is our commitment that as we return to in-person events, they can do this effectively, safely and with confidence.

All in-person Kisaco Research events will prioritize the health and safety of colleagues and customers and, in the first instance, will be run in accordance with official government and local authority guidance, as well as any venue or location-specific regulations.

Kisaco Research is committed to following the Association of Event Organisers All Secure Standard, which has been approved by by UK Government.

Download the Kisaco Research Returning Safely Measures 

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us